MA44207A - Immunoglobulines conjuguées cys80 - Google Patents
Immunoglobulines conjuguées cys80Info
- Publication number
- MA44207A MA44207A MA044207A MA44207A MA44207A MA 44207 A MA44207 A MA 44207A MA 044207 A MA044207 A MA 044207A MA 44207 A MA44207 A MA 44207A MA 44207 A MA44207 A MA 44207A
- Authority
- MA
- Morocco
- Prior art keywords
- immunoglobulins
- chain variable
- cys80
- immunoglobulin
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des procédés de génération d'immunoglobulines conjuguées, le procédé comprenant : le décoiffage d'une cystéine à la position d'acide aminé 80 ("cys80") dans une région variable de chaîne légère d'une immunoglobuline, l'immunoglobuline comprenant une région variable de chaîne lourde et la région variable de chaîne légère ; et la conjugaison d'un composé réactif avec thiol avec cys80, le composé réactif avec thiol comprenant un groupe réactif avec thiol. L'invention concerne en outre des molécules de liaison d'antigène et des procédés de génération de celles-ci, des immunoglobulines ainsi que des molécules d'acide nucléique codant pour les immunoglobulines et des cellules hôtes comprenant les molécules d'acide nucléique, des immunoglobulines conjuguées, et des régions variables de chaîne légère pour utilisation dans une immunoglobuline conjuguée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182020P | 2015-06-19 | 2015-06-19 | |
| PCT/US2016/038041 WO2016205618A1 (fr) | 2015-06-19 | 2016-06-17 | Immunoglobulines conjuguées cys80 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44207A true MA44207A (fr) | 2018-12-26 |
| MA44207B1 MA44207B1 (fr) | 2020-11-30 |
Family
ID=56404289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44207A MA44207B1 (fr) | 2015-06-19 | 2016-06-17 | Immunoglobulines conjuguées cys80 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10273310B2 (fr) |
| EP (2) | EP3795591B1 (fr) |
| JP (2) | JP6823606B2 (fr) |
| KR (1) | KR102718129B1 (fr) |
| CN (1) | CN107949575B (fr) |
| AU (1) | AU2016280190B9 (fr) |
| CA (1) | CA2989637C (fr) |
| CL (1) | CL2017003273A1 (fr) |
| CO (1) | CO2017013303A2 (fr) |
| CY (1) | CY1123481T1 (fr) |
| DK (2) | DK3795591T5 (fr) |
| ES (2) | ES2967613T3 (fr) |
| HR (1) | HRP20201489T1 (fr) |
| HU (2) | HUE051315T2 (fr) |
| IL (1) | IL256263B (fr) |
| LT (1) | LT3310816T (fr) |
| MA (1) | MA44207B1 (fr) |
| MD (1) | MD3310816T2 (fr) |
| MX (1) | MX389687B (fr) |
| MY (1) | MY189024A (fr) |
| PE (1) | PE20180498A1 (fr) |
| PH (2) | PH12021551939A1 (fr) |
| PL (1) | PL3310816T3 (fr) |
| PT (1) | PT3310816T (fr) |
| RS (1) | RS60943B1 (fr) |
| RU (1) | RU2756101C2 (fr) |
| SG (1) | SG10201913935RA (fr) |
| SI (1) | SI3310816T1 (fr) |
| SM (1) | SMT202000633T1 (fr) |
| UA (2) | UA124830C2 (fr) |
| WO (1) | WO2016205618A1 (fr) |
| ZA (2) | ZA201708619B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021090062A1 (fr) * | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Conjugués anticorps-médicament d'éribuline dirigés contre la mésothéline et procédés d'utilisation |
| CA3167317C (fr) * | 2020-02-12 | 2025-05-27 | Eli Lilly And Company | Cristallisation d'anticorps ou de fragments de liaison à l'antigène |
| EP4161966A1 (fr) | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Conjugués anticorps anti-bcma-médicament et procédés d'utilisation |
| CN112694521B (zh) * | 2020-12-02 | 2023-01-17 | 杭州百凌生物科技有限公司 | 一种人工多肽lh、其抗体及在病理检测中的应用 |
| IL322523A (en) | 2023-02-28 | 2025-10-01 | Eisai R&D Man Co Ltd | Anti-PSMA antibodies, conjugates and methods of use |
| WO2025199464A1 (fr) | 2024-03-22 | 2025-09-25 | Eisai R&D Management Co., Ltd. | Conjugués anticorps-médicament anti-trop2 et procédés d'utilisation |
| US20260042864A1 (en) * | 2024-08-09 | 2026-02-12 | Watchmaker Genomics, Inc. | Hot-start antibodies for taq dna polymerase variant |
| WO2026044149A2 (fr) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthèse de combinaisons médicament-lieur pour conjugués anticorps-médicament |
| US20260139068A1 (en) | 2024-08-21 | 2026-05-21 | Eisai R&D Management Co., Ltd. | Anti-cd73 antibodies, conjugates, and methods of use |
| WO2026071051A1 (fr) * | 2024-09-27 | 2026-04-02 | 東レ株式会社 | Agent réducteur pour éliminer la coiffe d'une immunoglobuline ou d'un fragment de liaison à l'antigène de celle-ci |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69936409T2 (de) * | 1998-04-28 | 2008-04-17 | Laboratoires Serono S.A., Coinsins | Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide |
| US6904369B1 (en) * | 2000-06-29 | 2005-06-07 | The Trustees Of Columbia University In The City Of New York | Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor |
| US7402409B2 (en) | 2003-01-23 | 2008-07-22 | Epitomics, Inc. | Cell fusion method |
| CN100415765C (zh) * | 2003-08-07 | 2008-09-03 | 宜康公司 | 兔单克隆抗体的人源化方法 |
| WO2006017759A2 (fr) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Anticorps fixant le marqueur specifique des cellules endotheliales (tem1) et leurs utilisations |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
| PT2164868E (pt) * | 2007-05-04 | 2015-08-04 | Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa | Domínios variáveis de anticorpos de coelho manipulados e suas utilizações |
| NZ601583A (en) * | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| KR20100107501A (ko) * | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| WO2009117531A1 (fr) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Conjugués auristatine-lieur de médicament |
| US20100260769A1 (en) | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
| CA3220104A1 (fr) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Anticorps et conjugues modifies par la cysteine |
| SG186451A1 (en) * | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
| CN102008732B (zh) * | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | 一种叶酸偶联抗体药物及其制备方法与应用 |
| WO2014031476A1 (fr) * | 2012-08-21 | 2014-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps monoclonaux spécifiques au domaine de la mésothéline et utilisation de ces derniers |
| MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| JP2016531915A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス, インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
-
2016
- 2016-06-17 EP EP20192124.4A patent/EP3795591B1/fr active Active
- 2016-06-17 LT LTEP16736952.9T patent/LT3310816T/lt unknown
- 2016-06-17 RU RU2017146220A patent/RU2756101C2/ru active
- 2016-06-17 PH PH1/2021/551939A patent/PH12021551939A1/en unknown
- 2016-06-17 PL PL16736952T patent/PL3310816T3/pl unknown
- 2016-06-17 CA CA2989637A patent/CA2989637C/fr active Active
- 2016-06-17 SG SG10201913935RA patent/SG10201913935RA/en unknown
- 2016-06-17 KR KR1020187001769A patent/KR102718129B1/ko active Active
- 2016-06-17 SI SI201630933T patent/SI3310816T1/sl unknown
- 2016-06-17 SM SM20200633T patent/SMT202000633T1/it unknown
- 2016-06-17 HU HUE16736952A patent/HUE051315T2/hu unknown
- 2016-06-17 DK DK20192124.4T patent/DK3795591T5/da active
- 2016-06-17 EP EP16736952.9A patent/EP3310816B1/fr active Active
- 2016-06-17 HU HUE20192124A patent/HUE064407T2/hu unknown
- 2016-06-17 US US15/185,879 patent/US10273310B2/en active Active
- 2016-06-17 PT PT167369529T patent/PT3310816T/pt unknown
- 2016-06-17 HR HRP20201489TT patent/HRP20201489T1/hr unknown
- 2016-06-17 UA UAA201713079A patent/UA124830C2/uk unknown
- 2016-06-17 PE PE2017002753A patent/PE20180498A1/es unknown
- 2016-06-17 PH PH1/2017/502352A patent/PH12017502352B1/en unknown
- 2016-06-17 WO PCT/US2016/038041 patent/WO2016205618A1/fr not_active Ceased
- 2016-06-17 UA UAA202102151A patent/UA129321C2/uk unknown
- 2016-06-17 MX MX2017016674A patent/MX389687B/es unknown
- 2016-06-17 ES ES20192124T patent/ES2967613T3/es active Active
- 2016-06-17 RS RS20201246A patent/RS60943B1/sr unknown
- 2016-06-17 MD MDE20180417T patent/MD3310816T2/ro unknown
- 2016-06-17 DK DK16736952.9T patent/DK3310816T3/da active
- 2016-06-17 JP JP2017565751A patent/JP6823606B2/ja active Active
- 2016-06-17 MA MA44207A patent/MA44207B1/fr unknown
- 2016-06-17 MY MYPI2017001842A patent/MY189024A/en unknown
- 2016-06-17 AU AU2016280190A patent/AU2016280190B9/en active Active
- 2016-06-17 ES ES16736952T patent/ES2829251T3/es active Active
- 2016-06-17 CN CN201680035726.6A patent/CN107949575B/zh active Active
-
2017
- 2017-12-12 IL IL256263A patent/IL256263B/en unknown
- 2017-12-18 ZA ZA2017/08619A patent/ZA201708619B/en unknown
- 2017-12-19 CL CL2017003273A patent/CL2017003273A1/es unknown
- 2017-12-22 CO CONC2017/0013303A patent/CO2017013303A2/es unknown
-
2019
- 2019-03-14 US US16/353,326 patent/US11129904B2/en active Active
-
2020
- 2020-07-28 JP JP2020127204A patent/JP7042876B2/ja active Active
- 2020-10-20 CY CY20201100992T patent/CY1123481T1/el unknown
-
2021
- 2021-03-29 ZA ZA2021/02093A patent/ZA202102093B/en unknown
- 2021-09-02 US US17/464,815 patent/US20230001004A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44207B1 (fr) | Immunoglobulines conjuguées cys80 | |
| MA49599A1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
| NZ739721A (en) | Antigen binding constructs to target molecules | |
| BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| MA40510A (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t | |
| EA201791742A1 (ru) | Антитела, направленные против гена-3 активации лимфоцитов (lag-3) | |
| EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
| EA201491827A1 (ru) | Антитела против hla-b*27 и их применение | |
| MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
| EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| MX2009006891A (es) | Anticuerpos cd44. | |
| MX372817B (es) | Anticuerpos dirigidos contra la proteína muerte programada-1 (pd-1). | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| MX2021001672A (es) | Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. | |
| EA201892063A1 (ru) | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
| MX2014010449A (es) | Anticuerpos a metaloproteinasa de matriz 9. | |
| MA43028B1 (fr) | Anticorps bispécifiques pour pd1 et tim3 | |
| EP4356972A3 (fr) | Anticorps monoclonaux anti-annexine a2 | |
| EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
| EA202092981A1 (ru) | Антитела к l1cam и их применение | |
| MA41666B1 (fr) | Anticorps anti-ox40 et leurs utilisations |